CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

被引：0
|
作者：
M. V. Lima
G. S. Ribeiro
E. T. Mesquita
P. R. Victer
R. Vianna-Jorge
机构：
[1] Hospital Universitário Antônio Pedro,Departamento de Medicina Clínica
[2] Universidade Federal Fluminense,Departamento de Patologia
[3] Hospital Universitário Antônio Pedro,Departamento de Farmacologia Básica e Clínica
[4] Universidade Federal Fluminense,Coordenação de Pesquisa
[5] Universidade Federal do Rio de Janeiro,undefined
[6] Cidade Universitária,undefined
[7] Centro de Ciências da Saúde,undefined
[8] Instituto Nacional de Câncer,undefined
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Gene polymorphism; Brazilians; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 15
页数：6
相关论文
共 50 条
  • [31] Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms
    Mark W. Linder
    Stephen Looney
    Jesse E. Adams
    Nancy Johnson
    Deborah Antonino-Green
    Nichole Lacefield
    Bonny L. Bukaveckas
    Roland Valdes
    Journal of Thrombosis and Thrombolysis, 2002, 14 : 227 - 232
  • [32] Warfarin: CYP2C9 polymorphisms increase risk of bleeding events
    Reactions Weekly, 2002, 897 (1) : 4 - 4
  • [33] Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9
    Khaleqsefat, E.
    Khalaj-Kondori, M.
    Bonyadi, Jabbarpour M.
    Battaloglu, E.
    HIPPOKRATIA, 2017, 21 (02) : 93 - 96
  • [34] Warfarin dose requirements in a patient with the CYP2C9*14 allele
    Lee, Yee Ming
    Eggen, Jessica
    Soni, Vinay
    Drozda, Katarzyna
    Nutescu, Edith A.
    Cavallari, Larisa H.
    PHARMACOGENOMICS, 2014, 15 (07) : 909 - 914
  • [35] Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
    Linder, MW
    Looney, S
    Adams, JE
    Johnson, N
    Antonino-Green, D
    Lacefield, N
    Bukaveckas, BL
    Valdes, R
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2002, 14 (03) : 227 - 232
  • [36] Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients
    Nassr Eldin M. A. Shrif
    Hong-Hee Won
    Seung-Tae Lee
    Jun-Hee Park
    Ka-Kyung Kim
    Min-Ji Kim
    Seonwoo Kim
    Soo-Youn Lee
    Chang-Seok Ki
    Ihsan M. Osman
    Enaam A. Rhman
    Ibtisam A. Ali
    M. N. A. Idris
    Jong-Won Kim
    European Journal of Clinical Pharmacology, 2011, 67 : 1119 - 1130
  • [37] Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients
    Shrif, Nassr Eldin M. A.
    Won, Hong-Hee
    Lee, Seung-Tae
    Park, Jun-Hee
    Kim, Ka-Kyung
    Kim, Min-Ji
    Kim, Seonwoo
    Lee, Soo-Youn
    Ki, Chang-Seok
    Osman, Ihsan M.
    Rhman, Enaam A.
    Ali, Ibtisam A.
    Idris, M. N. A.
    Kim, Jong-Won
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (11) : 1119 - 1130
  • [38] Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy
    Redman, Andrea R.
    Zheng, Jack
    Shamsi, Shahab A.
    Huo, Jingguo
    Kelly, Edward J.
    Ho, Rodney J. Y.
    Ritchie, Denise M.
    Hon, Yuen Yi
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2008, 14 (01) : 29 - 37
  • [39] Effects of rare CYP2C9 alleles on stable warfarin doses in Chinese Han patients with atrial fibrillation
    Wang, Dongxu
    Dai, Da-Peng
    Wu, Hualan
    Chong, Jia
    Lu, You
    Yin, Ruoyun
    Zhao, Xinlong
    Zhao, Anxu
    Yang, Jiefu
    Chen, Hao
    PHARMACOGENOMICS, 2020, 21 (14) : 1021 - 1031
  • [40] Cytochrome P4502C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients
    Siguret, V
    Gouin, I
    Golmard, JL
    Geoffroy, S
    Andreux, JP
    Pautas, E
    REVUE DE MEDECINE INTERNE, 2004, 25 (04): : 271 - 274
12345